DK277187A - Farmaceutisk komposition omfattende et ikke-toksisk, inert, farmaceutisk acceptabelt, vandigt baerermedium og en tumornekrosefaktor samt fremgangsmaade til fremstilling af kompositionen. - Google Patents

Farmaceutisk komposition omfattende et ikke-toksisk, inert, farmaceutisk acceptabelt, vandigt baerermedium og en tumornekrosefaktor samt fremgangsmaade til fremstilling af kompositionen.

Info

Publication number
DK277187A
DK277187A DK277187A DK277187A DK277187A DK 277187 A DK277187 A DK 277187A DK 277187 A DK277187 A DK 277187A DK 277187 A DK277187 A DK 277187A DK 277187 A DK277187 A DK 277187A
Authority
DK
Denmark
Prior art keywords
water
pharmaceutical composition
carriing
toxic
inert
Prior art date
Application number
DK277187A
Other languages
Danish (da)
English (en)
Other versions
DK277187D0 (da
Inventor
Nandini Katre
James William Thomson
Michael James Knauf
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK277187D0 publication Critical patent/DK277187D0/da
Publication of DK277187A publication Critical patent/DK277187A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK277187A 1986-05-29 1987-05-29 Farmaceutisk komposition omfattende et ikke-toksisk, inert, farmaceutisk acceptabelt, vandigt baerermedium og en tumornekrosefaktor samt fremgangsmaade til fremstilling af kompositionen. DK277187A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86876686A 1986-05-29 1986-05-29

Publications (2)

Publication Number Publication Date
DK277187D0 DK277187D0 (da) 1987-05-29
DK277187A true DK277187A (da) 1987-12-01

Family

ID=25352278

Family Applications (1)

Application Number Title Priority Date Filing Date
DK277187A DK277187A (da) 1986-05-29 1987-05-29 Farmaceutisk komposition omfattende et ikke-toksisk, inert, farmaceutisk acceptabelt, vandigt baerermedium og en tumornekrosefaktor samt fremgangsmaade til fremstilling af kompositionen.

Country Status (9)

Country Link
EP (1) EP0247860B1 (fi)
JP (1) JPS62289522A (fi)
AT (1) ATE77959T1 (fi)
AU (1) AU595321B2 (fi)
CA (1) CA1283046C (fi)
DE (1) DE3780218T2 (fi)
DK (1) DK277187A (fi)
FI (1) FI872393A (fi)
NO (1) NO872227L (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
EP0460101A4 (en) * 1989-02-24 1992-04-15 Immunotherapeutics, Inc. Immobilized cytokines
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1991001758A1 (en) * 1989-08-07 1991-02-21 Debiopharm S.A. Biologically active drug polymer derivatives
DE3936777A1 (de) * 1989-11-04 1991-05-08 Basf Ag Quervernetzte tumor-nekrose-faktoren
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
EP0553281B1 (en) * 1990-10-18 1995-05-31 The Board Of Regents, The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
ES2145744T5 (es) * 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
IT1291114B1 (it) * 1997-03-20 1998-12-29 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7179891B2 (en) 2002-03-25 2007-02-20 Tadanori Mayumi Physiologically active complex
JP4177604B2 (ja) * 2002-03-25 2008-11-05 株式会社林原生物化学研究所 生理活性複合体
TW200526780A (en) 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AU580431B2 (en) * 1985-06-26 1989-01-12 Cetus Corp Solubilization of proteins for pharmaceutical compositions using polymer conjugation

Also Published As

Publication number Publication date
CA1283046C (en) 1991-04-16
EP0247860B1 (en) 1992-07-08
FI872393A0 (fi) 1987-05-28
AU595321B2 (en) 1990-03-29
NO872227L (no) 1987-11-30
NO872227D0 (no) 1987-05-27
AU7347987A (en) 1987-12-03
DE3780218D1 (de) 1992-08-13
ATE77959T1 (de) 1992-07-15
DK277187D0 (da) 1987-05-29
JPS62289522A (ja) 1987-12-16
EP0247860A3 (en) 1989-10-11
EP0247860A2 (en) 1987-12-02
FI872393A (fi) 1987-11-30
DE3780218T2 (de) 1992-12-17

Similar Documents

Publication Publication Date Title
DK277187A (da) Farmaceutisk komposition omfattende et ikke-toksisk, inert, farmaceutisk acceptabelt, vandigt baerermedium og en tumornekrosefaktor samt fremgangsmaade til fremstilling af kompositionen.
MX174442B (es) Composiciones farmaceuticas y procedimiento para prepararlas
ES2061589T3 (es) Sistema de liberacion de principios activos implantable y biologicamente degradable.
IT1141954B (it) Procedimento per ottenere eparine di basso peso molecolare dotate di proprieta' farmacologiche elevate,e prodotto cosi' ottenuto
FI885109A (fi) Foerfarande foer solidifikation och inkapsling med anvaendning av kaern-skalpolymerpartiklar.
AU5469990A (en) Water soluble high molecular polymerized drug preparation
FI853026A0 (fi) Framstaellning av 3-acylaminoimidazol/1,2-c/pyridinderivat och deras terapeutiska tillaempning.
EP0169443A3 (en) Tricyclic dihydropyridazinones and pharmaceutical compositions contaning them
FR2377381A1 (fr) Derives de piperidine et leur utilisation comme stabilisants de polymeres
ITMI911950A1 (it) Sistema terapeutico transdermale per la somministrazione di farmaci ad attivita' broncodilatante.
FI916076A0 (fi) Agaricida kompositioner och foerfarande foer framstaellning av dessa.
DE69003466D1 (de) Substituierte Thienopyrimidin-Derivate, deren Herstellung, pharmazeutische Zusammensetzungen und medizinische Verwendung.
ATE96668T1 (de) Pharmazeutische zusammensetzung, die ein hydantoin-derivat enthaelt.
FI793039A (fi) Oktahydro-1h-benso(4,5)-furo(3,2-e)-isokinoliner med analgetiska och narkotikaantagonistiska egenskaper
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
JPS56155286A (en) Water-absorbing agent composition for soil
IL74692A0 (en) Pharmaceutical compositions comprising 4,9-dihydro-4(1-methyl-4-piperidinylidene)-10h-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one and a biodegradable polymer
IT8025473A0 (it) Derivati piridossinici ad attivita' terapeutica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
FR2616326B1 (fr) Compositions therapeutiques a base de nouveaux aminoacylates d'acetal du glycerol
ITMI932377A0 (it) Composizioni terapeutiche ad attivita' antitumorale a base di derivati 1,3,8,10 tetrasostituiti del 4,5,6,7-tetratiocino (1,2-b: 3,4-b') diimidazolil-2,9 ditione
IL74692A (en) Pharmaceutical compositions comprising 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)-cyclohepta(1,2-b)-thiophen-10-one and a biodegradable polymer

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment